Abstract: The present disclosure relates generally to the use of methazolamide in therapy. The disclosure further relates to treating liver dysfunction, or improving liver function, in a patient.

Abstract: The present disclosure relates generally to the use of methazolamide in therapy. The disclosure particularly relates to regulation of glucose homeostasis and reduction of body mass in patients suffering from or susceptible to diseases and associated conditions, in which undesirably high blood glucose levels are involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present disclosure further relates to compounds and agents and compositions thereof for use in the treatment methods.

Abstract: The present disclosure relates generally to the use of methazolamide in therapy. The disclosure particularly relates to regulation of glucose homeostasis and reduction of body mass in patients suffering from or susceptible to diseases and associated conditions, in which undesirably high blood glucose levels are involved or implicated, such as diabetes, syndrome X, hyper-glycaemia, vascular disease and kidney disease. The present disclosure further relates to compounds and agents and compositions thereof for use in the treatment methods.

Abstract: The present disclosure relates generally to the use of methazolamide in therapy. The disclosure further relates to treating liver dysfunction, or improving liver function, in a patient.

Abstract: It relates generally to the field of drug identification and evaluation and therapeutic optimization. More particularly, it provides a protocol for identifying compounds useful in the treatment of TNF? associated diabetes or a condition associated with diabetes based on a signature of genomic or proteomic expression. Diagnostic and prognostic protocols for diabetes and conditions associated therewith are also provided. Further, optimization of therapeutic intervention is also provided.

Abstract: The present invention relates generally to a method of modulating the functional activity of a serum amyloid A or derivative, homologue, analogue, equivalent or mimetic thereof and, more particularly, to a method of modulating the functional activity of a serum amyloid A by modulating intracellular levels of Tanis or derivative, homologue, analogue, chemical equivalent or mimetic thereof. The method of the present invention is particularly useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate serum amyloid A activity. The present invention is further directed to methods for identifying and/or designing agents capable of modulating Tanis mediated regulation of a serum amyloid A functional activity.

Abstract: The present invention relates generally to a ligand for a protein associated with modulating obesity, diabetes and metabolic energy levels in animals including humans. More particularly, the present invention provides a ligand of the protein, Beacon, and its homologs. The identification of a Beacon ligand permits the identification of agents which agonize or antagonize the Beacon-ligand interaction and, hence, the development of therapeutic molecules useful in modulating obesity, diabetes and/or energy imbalance.

Abstract: An isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding a molecule or derivative or homologue thereof wherein said nucleic acid molecule is expressed in a larger amount in one or both hypothalamus tissue or muscle tissue of obese animals compared to lean animals or in fed animals compared to fasted animals. Nucleic acid sequences are disclosed. It is proposed to use the expression products of such nucleic acids as modulators and/or monitors of physiological processes associated with obesity, anorexia, weight maintenance, impaired muscle development, diabetes and/or metabolic energy levels.

Abstract: The present invention relates generally to a nucleic acid molecule which is expressed in at least red gastrocnemius muscle or its equivalent under particular physiological conditions. It is proposed that the nucleic acid molecule is differentially expressed under differing conditions of healthy state, myopathy, obesity, anorexia, weight maintenance, diabetes, disorders associated with mitochondrial dysfunction, genetic disorders, cancer, heart disease, inflammation, disorders associated with the immune system, infertility, disease associated with the brain and/or metabolic energy levels.

Abstract: The present invention relates generally to nucleic acid molecules expressed at least in the hypothalamus, liver, mesenteric adipose tissue, or red gastrocnemius muscle conveniently identified using differential display techniques under differing physiological conditions. The nucleic acid molecules are associated with or act as markers for conditions of inter alia a healthy state, myopathy, obesity, anorexia, weight maintenance, diabetes, disorders associated with mitochondrial dysfunction, genetic disorders and/or metabolic energy levels. More particularly, the present invention is directed to a nucleic acid molecule and/or its expression product for use in therapeutic and diagnostic protocols for conditions such as inter alia a myopathy, obesity, anorexia, weight maintenance, diabetes, disorders associated with mitochondrial dysfunction, genetic disorders and/or metabolic energy levels.

Abstract: The present invention relates generally to a ligand for a protein associated with modulating obesity, diabetes and metabolic energy levels in animals and humans and to genetic sequences encoding the ligand. More particularly, the present invention is directed to a ligand of the protein “beacon” and its homologues. The identification of the ligand molecule permits the development of a range of therapeutic and diagnostic protocols for obesity, diabetes and energy imbalance.

Abstract: The present invention relates generally to a nucleic acid molecule which is expressed in at least the stomach, hypothalamus or liver identified using differential display techniques under differing physiological conditions. It is proposed that the nucleic acid molecules encode expression products associated with the modulation of obesity, anorexia, weight maintenance, diabetes and/or metabolic energy levels. More particularly, the present invention is directed to nucleic acid molecules and expression products produced by recombinant means from the nucleic acid molecule or isolated from natural sources and their use in therapeutic and diagnostic protocols for conditions such as obesity, anorexia, weight maintenance, diabetes and/or energy imbalance.

Abstract: The present invention relates generally to nucleic acid molecules expressed at least in the hypothalamus, liver or pancreas identified using differential display techniques under differing physiological conditions. The nucleic acid molecules are associated with or act as markers for conditions of a healthy state, obesity, anorexia, weight maintenance, diabetes and/or metabolic energy levels. More particularly, the present invention is directed to a nucleic acid molecule and/or its expression product for use in therapeutic and diagnostic protocols for conditions such as obesity, anorexia, weight maintenance, diabetes and energy imbalance. The subject nucleic acid molecule and expression product and their derivatives, homologs, analogs and mimetics are proposed to be useful, therefore, as therapeutic and diagnostic agents for obesity, anorexia, weight maintenance, diabetes and energy imbalance or as targets for the design and/or identification of modulators of their activity and/or function.

Abstract: An isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complimentary to a sequence encoding a molecule or derivative or homologue thereof wherein said nucleic acid molecule is expressed in a larger amount in one or both hypothalamus tissue or muscle tissue of obese animals compared to lean animals or in fed animals compared to fasted animals. Nucleic acid sequences are disclosed. It is proposed to use the expression products of such nucleic acids as modulators and/or monitors of physiological processes associated with obesity, anorexia, weight maintenance, impaired muscle development, diabetes and/or metabolic energy levels.

Abstract: The present invention relates generally to a method of modulating the functional activity of a serum amyloid A or derivative, homologue, analogue, equivalent or mimetic thereof and, more particularly, to a method of modulating the functional activity of a serum amyloid A by modulating intracellular levels of Tanis or derivative, homologue, analogue, chemical equivalent or mimetic thereof. The method of the present invention is particularly useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate serum amyloid A activity. The present invention is further directed to methods for identifying and/or designing agents capable of modulating Tanis mediated regulation of a serum amyloid A functional activity.

Abstract: The present invention relates generally to nucleic acid molecules at least expressed in liver or stomach tissue and identified using a differential display or macroarray technique or another technique capable of detecting differential expression of nucleic acid molecules under differing physiological conditions. Expression products from the nucleic acid molecules of the present invention are associated with or act as markers for one or more of a healthy state, obesity, anorexia, weight maintenance, impaired muscle development, diabetes and/or metabolic energy levels and/or altered physiological conditions.